Intuitive Surgical (ISRG) reported robust second-quarter 2026 financial results, driven by significant growth in both its core da Vinci and newer Ion robotic surgery platforms. Total revenue reached $2.89 billion, representing a 19% year-over-year increase from the prior year's $2.44 billion. This expansion was fueled...
Intuitive Surgical announced its first quarter 2026 financial results today, reporting significant growth across its global portfolio of robotic-assisted surgery technologies. Worldwide procedures combining both da Vinci and Ion systems grew approximately 17% compared to the first quarter of 2025. The company placed 431 da...
Intuitive Surgical (ISRG) shares fell 37% to $355 following Q2 earnings, where the company beat revenue estimates with 19% growth and non-GAAP EPS of $2.80. Despite the financial beat, management cut full-year procedure growth guidance for the da Vinci system to a range of 13.5%-15.5%,...
Intuitive Surgical (ISRG) reported standout Q1 2023 results, beating analyst estimates with revenue of $1.70 billion, a 14% year-over-year increase, and adjusted earnings of $1.23 per share versus the expected $1.20. The surge was driven by a 26% jump in procedure volumes as hospitals cleared...
Intuitive Surgical reported its Q1 earnings with a notably upbeat tone, driven by strong revenue growth of 23% year over year to $2.77 billion. Recurring revenue increased 23% to $2.4 billion, now representing 86% of total sales, which underscores the company's annuity-like business model favored...
Intuitive Surgical (ISRG) saw its stock rise approximately 7% in intraday trading following the release of better-than-expected Q1 earnings results, with revenue increasing by roughly 23% year-over-year and non-GAAP net income climbing around 36% year-over-year. The company's performance exceeded consensus estimates, prompting Wall Street analysts...
Intuitive Surgical (ISRG) is preparing to release its Q2 2026 earnings results after market close on Thursday, July 16th. Analysts project the company will report earnings per share of $2.48 and revenue of $2.8249 billion for the quarter. The upcoming earnings call is scheduled for...
Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK) are identified as key players where surgical robotics integrates with artificial intelligence capabilities. Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66%, with revenue reaching $2.77 billion. The company's installed base of da...
Intuitive Surgical (ISRG) stock surged 7.2% on Wednesday to close at $483.62 after the company reported stronger-than-expected first-quarter results and raised its full-year procedural outlook. The medical technology giant beat estimates with quarterly sales growing 23% year-over-year to $2.77 billion, compared to analyst expectations of...
Intuitive Surgical (NASDAQ:ISRG) reported strong fiscal Q2 results with revenue increasing 19% year-over-year to $2.89 billion, driven by a 15% rise in worldwide da Vinci procedure volumes. The company's recurring revenue model proved resilient as instruments and accessories revenue grew 18% to $1.73 billion, reflecting...
Intuitive Surgical reported robust financial performance for the second quarter of 2026, generating USD 2.89 billion in revenue. This figure represents an 18.5 percent increase compared to the same period in the prior year and exceeded analyst estimates by 2.6 percent, indicating strong commercial execution...
Intuitive Surgical (ISRG) shares edged higher on September 17, 2026, closing at USD 383.54 on the Nasdaq following a significant regulatory milestone and strong quarterly performance. The company received CE mark approval in Europe for its da Vinci SP single-port robotic system to perform transvaginal...
HSBC downgraded Intuitive Surgical (NASDAQ:ISRG) from a Buy to a Hold rating, setting a $391 target price. This move follows a series of recent analyst adjustments, including Sanford Bernstein lowering its target to $685 and Jefferies reducing its objective to $515, though the consensus remains...
Intuitive Surgical (NASDAQ:ISRG) saw a mixed institutional landscape in the first quarter, highlighted by ABN AMRO Bank N.V. reducing its stake by 37.1% to 40,572 shares, worth approximately $18.9 million. Conversely, several smaller hedge funds including Riversedge Advisors LLC and Fiduciary Financial Group LLC increased...
Intuitive Surgical (ISRG) reported a record first quarter with revenue climbing 23% to $2.77 billion and earnings per share of $2.50, significantly beating the analyst consensus of $2.08. Despite these strong fundamentals, shares dropped approximately 25% since the start of the year, trading around EUR...
Intuitive Surgical, Inc. (ISRG) has been a trending stock, outperforming the broader market with shares rising 10.1% over the past month compared to the S&P 500's 1% gain. The company recently reported quarterly revenues of $2.89 billion, beating the consensus estimate of $2.81 billion by...
Intuitive Surgical (NASDAQ:ISRG) EVP Mark Brosius sold 46 shares of the company's stock on September 8th under a pre-arranged Rule 10b5-1 trading plan. The transaction, valued at $16,616.58, reduced his personal holding by 5.22%, leaving him with 835 shares worth approximately $301,627. This insider sale...
Intuitive Surgical (ISRG) is trading at a forward 12-month P/E of 30.26X, significantly below its 10-year median of 58.18X and historical high of 93.22X, marking its cheapest valuation in a decade following a price decline exceeding 40%. Despite the steep multiple compression, the company maintains...
Intuitive Surgical (ISRG) remains the undisputed leader in robotic-assisted surgery, trading at a premium valuation of 42.5 times earnings compared to peers like Medtronic at 24.2x. Despite commanding the highest operating margin in its peer group at 31% and delivering robust revenue growth of 21%...
Intuitive Surgical (ISRG) EVP Mark Brosius sold 77 shares of the company's stock on August 17th for a total value of $30,081.59 at an average price of $390.67 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a...
